Recombinant humanized monoclonal antibody antiIL-1β(Cp Guojian)

重组抗IL-1β人源化单克隆抗体（三生国健）

Report date: 2025/06/16 14:54:02

Base Information

Drug NameRecombinant humanized monoclonal antibody antiIL-1β(Cp Guojian)
Drug Alias NameRecombinant Anti-IL-1β Humanized Monoclonal Antibody(Cp Guojian)SSGJ-613
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionInterleukin-1 beta inhibitors
TargetsInterleukin-1 beta
Therapy Area/IndicationsInflammationArthritis, GoutyGout +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, GoutyGoutArthritis, Juvenile +[5] 
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A